(SLB, BIOD, INSM) CRWENewswire Stocks In Action
Insmed Inc - INSM - reported that the FDA has lifted the clinical hold previously placed on ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria lung disease. Schlumberger Ltd - SLB - posted full-year 2011 revenue of $39.54 billion versus $27.45 billion in 2010. and lastly; Biodel Inc - BIOD - reported that the European Medicines Agency’s Committee for Orphan Medicinal Products has recommended that Biodel’s Stabilized Glucagon for the treatment of congenital hyperinsulinism be granted Orphan Medicinal Product Designation.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

ユーザー：karmastock
再生時間：00:01:13
投稿日時：12/01/21 3:45
カテゴリ：ビジネス全般 
タグ： INSM  SLB  BIOD  Nasdaq:INSM  NYSE:SLB  Nasdaq:BIOD 

[ 前ページへ戻る ]